Double Blind Bio
Double Blind Bio provides AI agents that automate site selection, feasibility, and startup workflows for clinical trials, helping sponsors and research sites reduce manual effort and accelerate study timelines. The platform embeds agents directly into existing systems to handle repetitive tasks like feasibility form generation, site matching, and outreach, with intelligence that compounds across deployments. It serves both life sciences companies and clinical research sites seeking faster trial activation without adding headcount.
- Artificial Intelligence
- AI Agents
- Healthcare Technology
- Software Only
Funding
Raised to date
$12.6MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 3 rounds
$7M · Seed
Announced Aug 2026 · from article date
Disclosed cumulative: $12.6M
Founders
Product
Problem
Clinical trials are slowed by administrative friction unrelated to science, including repetitive manual work at research sites, sponsors chasing updates, and delays that compound before being noticed. Site selection often defaults to familiar choices rather than the best options due to fragmented data and no easy way to compare site performance, leading to slower enrollment and suboptimal trial execution.
Solution
Double Blind Bio builds AI agents that work inside real workflows to automate busywork across the trial lifecycle, from feasibility to startup to execution. The agents act directly in the systems teams already use, handling repetitive tasks so humans can focus on judgment and execution. For sponsors, the platform enables better site selection, faster activation, and improved trial tracking without adding headcount. For sites, AI agents help find relevant trials earlier, respond faster to opportunities, and reduce time spent on business development and feasibility administration. Every deployment compounds intelligence across trials, improving site selection, execution, and outcomes over time.
Target Audience
Primary customers are life sciences companies including biotech and pharma sponsors, as well as clinical research sites and site networks that conduct, support, or participate in clinical research.
Features
- Curated and dynamically updated database of sites with advanced filtering by therapeutic area, trial experience, geographic reach, patient population access, and historical performance
- Automated generation, pre-filling, and submission of feasibility forms using natural language inputs from protocols and site profiles
- AI-powered intelligent assistant for sites to manage inbound and outbound business development efforts with sponsors, including tracking sponsor interest and generating outreach content
- Structured sponsor data intelligence and predictive insights on upcoming trials, conference abstracts, and public datasets to inform site engagement strategies
- Automated document generation and trial startup operations support, including regulatory packet preparation and site task tracking
- Dashboards and metrics to assess site activity, engagement, feasibility performance, and business development outcomes